In vivo CAR T-cell Market
完整報告名稱與涵蓋範圍
In vivo CAR T-cell Market Size, Share & Trends Analysis Distribution by Delivery Systems (Lipid Nanoparticles (LNPs), Viral Vectors, Oncolytic Viruses), Targets (Hematological Cancers, Solid Tumors, Non-Oncology) and Segment Forecasts, 2025-2034
報告摘要
A CAGR of 32.9% is forecasted for the global In vivo CAR T-cell Market over the assessment period of 2025 through 2034.
In vivo CAR T-cell covers a promising development in cancer immunotherapy, enabling the genetic modification of a patient's t cells within the body to target cancer cells. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is propelled by a convergence of factors: rising awareness among end users, continuous product innovation, and the growing emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global In vivo CAR T-cell Media Market Snapshot
Chapter 4. Global In vivo CAR T-cell Media Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on In vivo CAR T-cell Media Market Industry Trends
4.10. Global In vivo CAR T-cell Media Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. In vivo CAR T-cell Media Market Segmentation 1: By Delivery Systems, Estimates & Trend Analysis
5.1. Market Share by Delivery Systems, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Systems:
5.2.1. Lipid Nanoparticles (LNPs)
5.2.2. Viral Vectors
5.2.3. Oncolytic Viruses
Chapter 6. In vivo CAR T-cell Media Market Segmentation 2: By Targets, Estimates & Trend Analysis
6.1. Market Share by Targets, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the
following Targets:
6.2.1. Hematological Cancers
6.2.2. Solid Tumors
6.2.3. Non-Oncology
Chapter 7. Plant-Based Vaccines Market Segmentation 3: By Target Antigen, Estimates & Trend Analysis
7.1. Market Share by Target Antigen, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Antigen:
7.2.1. CD19
7.2.2. BCMA
7.2.3. CD20
7.2.4. CD22
7.2.5. Others
Chapter 8. Plant-Based Vaccines Market Segmentation 4: By End-User, Estimates & Trend Analysis
8.1. Market Share by End-User, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
8.2.1. Hospitals
8.2.2. Cancer Treatment Centers
8.2.3. Outpatient Clinics
Chapter 9. Plant-Based Vaccines Market Segmentation 4: By Payload Type, Estimates & Trend Analysis
9.1. Market Share by Payload Type, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Payload Type:
9.2.1. DNA-Based
9.2.2. mRNA-Based
9.2.3. Circular RNA (oRNA)
Chapter 10. Plant-Based Vaccines Market Segmentation 4: Regional Estimates & Trend Analysis
10.1. Global Plant-Based Vaccines Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.2.3. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.2.4. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.2.5. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3. Europe
10.3.1. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.3.3. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.3.4. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.3.5. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.4.3. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.4.4. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.4.5. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5. Latin America
10.5.1. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.5.3. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.5.4. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.5.5. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.6.3. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.6.4. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.6.5. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Byterna Therapeutics
11.2.2. Thunder Biotech
11.2.3. Singular Immune
11.2.4. NanoCell Therapeutics
11.2.5. Jenthera Therapeutics
11.2.6. Acuitas Therapeutics
11.2.7. EsoBiotec (AstraZeneca)
11.2.8. CDR3 Therapeutics
11.2.9. Everest Medicines
11.2.10. Mustang Bio
11.2.11. Novartis
11.2.12. Capstan Therapeutics
11.2.13. Myeloid Therapeutics
11.2.14. CARISMA Therapeutics
11.2.15. Legend Biotech
11.2.16. Innorna
11.2.17. Genocury Biotech
11.2.18. Abintus Bio
11.2.19. Moderna
11.2.20. Strand Therapeutics
11.2.21. Coastar Therapeutics
11.2.22. A Sail Biomedicines
11.2.23. Orna Therapeutics
11.2.24. Nona Biosciences
11.2.25. Interius BioTherapeutics
11.2.26. TriArm Therapeutics
11.2.27. Sanofi
11.2.28. AbbVie
11.2.29. Shanghai Simnova Biotech
11.2.30. Umoja Biopharma
11.2.31. Astellas (Xyphos Biosciences)
11.2.32. Theorna
11.2.33. Kelonia Therapeutics
11.2.34. Pregene
11.2.35. Alaya.bio
11.2.36. EXUMA Biotech
11.2.37. Sana Biotechnology
11.2.38. Velvet Therapeutics
11.2.39. Deliver Biosciences
11.2.40. Vyriad
11.2.41. Imanis Life Sciences
11.2.42. CancerVAX
11.2.43. IASO Bio
11.2.44. Ensoma
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們